NutriStack
Potassium and Sacubitril/Valsartan, a caution.
Sacubitril/valsartan combines neprilysin inhibition with angiotensin receptor blockade and meaningfully raises serum potassium by suppressing aldosterone. In the PARADIGM-HF heart-failure trial, hyperkalemia greater than 5.4 mmol/L occurred in roughly 20% of treated patients. Adding a potassium supplement on top of this layered RAAS blockade can push potassium into dangerous territory, particularly in patients with chronic kidney disease or those also on spironolactone, eplerenone, or NSAIDs.
One pair, every claim cited. The two substances, the type, the mechanism, the recommendation, and the primary literature.
Same shape as the other 1,729 pairs in the public database.
From the interaction database
What the row says.
Every entry follows the same shape: what is happening, the mechanism, the recommendation, and the primary literature.
At a glance
- Substances
- Potassium and Sacubitril/Valsartan
- Pair type
- Caution
- Evidence (highest tier)
- Strong
- Source citations
- 2 sources
- Stack Score effect
- −5 to your Stack Score (per scored caution row).
- Scope
- Supplement × Prescription
- Last verified
- May 30, 2026
Caution · Strong evidence
Caution
What is happening. Sacubitril/valsartan combines neprilysin inhibition with angiotensin receptor blockade and meaningfully raises serum potassium by suppressing aldosterone. In the PARADIGM-HF heart-failure trial, hyperkalemia greater than 5.4 mmol/L occurred in roughly 20% of treated patients. Adding a potassium supplement on top of this layered RAAS blockade can push potassium into dangerous territory, particularly in patients with chronic kidney disease or those also on spironolactone, eplerenone, or NSAIDs.
Mechanism. Valsartan blocks the AT1 receptor and suppresses aldosterone-mediated potassium secretion. Sacubitril, as a neprilysin inhibitor, raises natriuretic peptides and can amplify natriuresis but does not offset the potassium retention; in heart failure patients, hyperkalemia remains a recognized class effect.
Recommendation. Do not take potassium supplements with sacubitril/valsartan unless your cardiologist has confirmed a true deficiency. If both are needed, get potassium checked within 1-2 weeks of starting and after every dose change. Avoid potassium-containing salt substitutes.
Sources (2)
- Desai AS, Vardeny O, Claggett B, McMurray JJ, Packer M, Swedberg K, Rouleau JL, Zile MR, Lefkowitz M, Shi V, Solomon SD. Reduced Risk of Hyperkalemia During Treatment of Heart Failure With Mineralocorticoid Receptor Antagonists by Use of Sacubitril/Valsartan Compared With Enalapril: A Secondary Analysis of the PARADIGM-HF Trial. JAMA Cardiol. 2017;2(1):79-85. PMID 27842179
- Heerspink HJ, Gao P, de Zeeuw D, Clase C, Dagenais GR, Sleight P, Lonn E, Teo KT, Yusuf S, Mann JF. The effect of ramipril and telmisartan on serum potassium and its association with cardiovascular and renal events: results from the ONTARGET trial. Eur J Prev Cardiol. 2014;21(3):299-309. PMID 24191305
Stack Score
How this pair moves the number.
Effect on the composite score
If both Potassium and Sacubitril/Valsartan are in the same stack, this pair applies −5 to your Stack Score (per scored caution row).
The full algorithm, the clamping rules, and four worked stacks are documented at /methodology/stack-score.
Check your full routine
One pair was the worked example. NutriStack runs every pair in your stack at once.
Drop in your supplements and prescriptions and the public database surfaces every interaction, synergy, timing rule, and contraindication, every one linked to its primary source.